Recurrent Small Cell Lung Cancer (SCLC) Completed Phase 1 Trials for Trastuzumab (DB00072)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00028535Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsTreatment